Coinfection  >>  Ximency (daclatasvir/asunaprevir/beclabuvir)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ximency (daclatasvir/asunaprevir/beclabuvir) / BMS
NCT02124044: Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV

Checkmark CROI 2015
Mar 2015 - Mar 2015: CROI 2015
Completed
2
30
US
Asunaprevir and Daclatasvir, Asunaprevir (ASV) and Daclatasvir (DCV), Asunaprevir and Daclatasvir with BMS-791325, Asunaprevir (ASV) and Daclatasvir (DCV) and BMS-791325 (Beclabuvir)
National Institutes of Health Clinical Center (CC), National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb
HIV-HCV
03/16
11/16

Download Options